Based on the key measurements obtained from Artiva Biotherapeutics,'s financial statements, Artiva Biotherapeutics, Common is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, Artiva Biotherapeutics,'s Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 102.5 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 11.1 M in 2024. Key indicators impacting Artiva Biotherapeutics,'s financial strength include:
Investors should never underestimate Artiva Biotherapeutics,'s ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Artiva Biotherapeutics,'s cash flow, debt, and profitability to make informed and accurate decisions about investing in Artiva Biotherapeutics, Common.
Net Income
(29.08 Million)
Artiva
Select Account or Indicator
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Effective Tax Rate
Company Equity Multiplier
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Net Debt
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Non Current Liabilities Other
Net Working Capital
Short Term Debt
Net Interest Income
Interest Income
Depreciation And Amortization
Selling General Administrative
Total Revenue
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Artiva Biotherapeutics, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Artiva Biotherapeutics,'s financial statements are interrelated, with each one affecting the others. For example, an increase in Artiva Biotherapeutics,'s assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Artiva Biotherapeutics,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Artiva Biotherapeutics, Common. Check Artiva Biotherapeutics,'s Beneish M Score to see the likelihood of Artiva Biotherapeutics,'s management manipulating its earnings.
Artiva Biotherapeutics, Stock Summary
Artiva Biotherapeutics, competes with Protagonist Therapeutics. Artiva Biotherapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Artiva Biotherapeutics,'s current stock value. Our valuation model uses many indicators to compare Artiva Biotherapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Artiva Biotherapeutics, competition to find correlations between indicators driving Artiva Biotherapeutics,'s intrinsic value. More Info.
Artiva Biotherapeutics, Common is rated second in return on equity category among its peers. It also is rated second in operating margin category among its peers . At this time, Artiva Biotherapeutics,'s Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Artiva Biotherapeutics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Artiva Biotherapeutics, Systematic Risk
Artiva Biotherapeutics,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Artiva Biotherapeutics, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Artiva Biotherapeutics, correlated with the market. If Beta is less than 0 Artiva Biotherapeutics, generally moves in the opposite direction as compared to the market. If Artiva Biotherapeutics, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Artiva Biotherapeutics, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Artiva Biotherapeutics, is generally in the same direction as the market. If Beta > 1 Artiva Biotherapeutics, moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Artiva Biotherapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Artiva Biotherapeutics,'s growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Artiva Biotherapeutics, growth as a starting point in their analysis.
Artiva Biotherapeutics, December 18, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Artiva Biotherapeutics, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Artiva Biotherapeutics, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Artiva Biotherapeutics, Common based on widely used predictive technical indicators. In general, we focus on analyzing Artiva Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Artiva Biotherapeutics,'s daily price indicators and compare them against related drivers.
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.